Analysis of Lipid Biomarkers of Exposure and Host Response

• Status: Unknown status
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this prospective, open-label, clinical trial is to establish the feasibility and validity of exhaled breath condensate (EBC) biomarkers for use in studies designed to evaluate harm reduction strategies of smoking. This will be accomplished by measuring selected markers in EBC believed related to the pathogenesis of lung disease before and after a smoking cessation intervention.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Nebraska
• Collaborator: Lorillard Tobacco Company
• Treatments: Nicotine

Criteria

Inclusion Criteria:

• Smoke at least 5 pack years

• Have a stable smoking habit for 3 months

• Be willing to make a serious quit attempt and

• Be able to use nicotine replacement therapy

Exclusion Criteria:

• Regular use of an anti-inflammatory medication

• Presence of an inflammatory lung disease

• Unstable medical condition